SRR8518342
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- XENOBIOTIC_METABOLISM+0.210
- MYC_TARGETS_V2+0.200
- FATTY_ACID_METABOLISM+0.190
- PEROXISOME+0.190
- E2F_TARGETS+0.180
- BILE_ACID_METABOLISM+0.150
Top 10 suppressed
- TGF_BETA_SIGNALING-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- UV_RESPONSE_DN-0.460
- ANGIOGENESIS-0.410
- MITOTIC_SPINDLE-0.340
- CHOLESTEROL_HOMEOSTASIS-0.320
- NOTCH_SIGNALING-0.320
- APICAL_JUNCTION-0.300
- HEDGEHOG_SIGNALING-0.240
- WNT_BETA_CATENIN_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2660032 | — | — | 0.825 |
| 2 | TCGA-A2-A04X-01A-21R-A034-07 | — | C | 0.809 |
| 3 | TCGA-55-8085-01A-11R-2241-07 | — | cohortA4 | 0.791 |
| 4 | SRR25617825 | — | C | 0.780 |
| 5 | TCGA-A8-A09M-01A-11R-A00Z-07 | — | B | 0.778 |
| 6 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.777 |
| 7 | TCGA-05-4389-01A-01R-1206-07 | — | cohortA4 | 0.775 |
| 8 | SRR8392897 | — | cohortSQ2 | 0.760 |
| 9 | TCGA-OL-A66H-01A-11R-A29R-07 | — | B | 0.755 |
| 10 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |